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Inositol 1,4,5-trisphosphate receptors (IP3Rs) are intracellular Ca
2+ channels that are widely expressed in
animal cells, where they mediate the release of Ca2+ from intracellular stores evoked by extracellular
stimuli. A diverse array of synthetic agonists of IP3Rs has deﬁned structure–activity relationships, but exist-
ing antagonists have severe limitations. We combined analyses of Ca2+ release with equilibrium compe-
tition binding to IP3R to show that (1,3,4,6)IP4 is a full agonist of IP3R1 with lower aﬃnity than (1,4,5)IP3.
Systematic manipulation of this meso-compound via a versatile synthetic scheme provided a family of
dimeric analogs of 2-O-butyryl-(1,3,4,6)IP4 and (1,3,4,5,6)IP5 that compete with (1,4,5)IP3 for binding to
IP3R without evoking Ca
2+ release. These novel analogs are the ﬁrst inositol phosphate-based competitive
antagonists of IP3Rs with aﬃnities comparable to that of the only commonly used competitive antagonist,
heparin, the utility of which is limited by oﬀ-target eﬀects.
Introduction
Inositol 1,4,5-trisphosphate receptors (IP3Rs) are intracellular
Ca2+ channels that are almost ubiquitously expressed in
animal cells.1,2 IP3Rs are essential links between receptors in
the plasma membrane that stimulate phospholipase C and
release of Ca2+ from the endoplasmic reticulum (ER). The
resulting cytosolic Ca2+ signals regulate many diverse cellular
processes.3 The three subtypes of IP3Rs expressed in ver-
tebrates (IP3R1-3) are closely related proteins and they are each
regulated by both (1,4,5)IP3 (1, Fig. 1) and Ca
2+, but they diﬀer
in their sensitivity to other forms of regulation and in their
subcellular and tissue distributions.1
Extensive structure–activity studies,4–8 reinforced by a high-
resolution structure of (1,4,5)IP3 bound to the IP3-binding core
of IP3R1 (Fig. 1A),
9 established that the vicinal 4,5-bisphos-
phate moiety is essential for (1,4,5)IP3 binding and the equa-
torial 6-hydroxyl and 1-phosphate confer high aﬃnity (Fig. 1B).
All high-aﬃnity agonists of IP3R have structures equivalent
to these substituents. The only endogenous inositol phos-
phate likely to bind to IP3Rs under physiological conditions is
(1,4,5)IP3, the immediate water-soluble product of phospho-
lipase C-catalyzed hydrolysis of the membrane lipid phos-
phatidylinositol 4,5-bisphosphate. However, synthetic ligands
of IP3Rs, including many inositol phosphates
7 and derivatives
of adenophostins,10–12 have provided insight into the struc-
tural determinants of IP3R activation. These ligands include
analogs of (1,4,5)IP3 that are resistant to degradation,
13 fluo-
rescent analogs,14 partial agonists,6 and synthetic derivatives
of adenophostins.10 There are, however, no ligands of IP3R
that distinguish eﬀectively between IP3R subtypes,
5,15,16 and
the only available antagonists have severe limitations.17 The
commonly used antagonists are heparin, 2-aminoethoxydiphe-
nyl borate (2-APB), xestospongins and high concentrations of
caﬀeine. The limitations of these antagonists include oﬀ-target
eﬀects, notably interactions with other Ca2+ channels, Ca2+
pumps, G proteins and other signalling pathways; membrane-
impermeability (heparin) and, for xestospongins, an inconsist-
ent history of eﬀectiveness as discussed recently.17 This study
was undertaken with the aim of developing more eﬀective
antagonists of IP3R.
(1,3,4,6)IP4, which retains the essential pharmacophore
of an IP3R agonist (Fig. 1B), stimulates Ca
2+ release via IP3R,
but its aﬃnity is between 10 and 100-fold lower than that of
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(1,4,5)IP3.
18–21 Some,19,22 though not all,21 studies have
suggested that (1,3,4,6)IP4 may be a partial agonist, namely
that it less eﬀectively activates IP3R than full agonists like
(1,4,5)IP3. It seems likely that the inverted position of the 2-OH
in (1,3,4,6)IP4 (equivalent to the 3-OH of (1,4,5)IP3 when the
structures are compared in orientations likely to reflect their
interactions with IP3R, Fig. 1B) is a major determinant of the
reduced aﬃnity.5,20 Although (1,3,4,6)IP4 is produced endogen-
ously from (1,3,4)IP3, it is unlikely to attain concentrations
that regulate IP3Rs.
24 Nevertheless, we chose (1,3,4,6)IP4 to
attempt development of novel antagonists of IP3R because it
and analogs in which its free hydroxyls are modified (3, 4) are
meso compounds that make synthesis more straightforward,
and we had initially supposed that (1,3,4,6)IP4 might have
reduced eﬃcacy.19,22 We previously reported that dimers of
inositol phosphates are high-aﬃnity partial agonists of IP3R.
6
We have now developed a family of antagonists of IP3Rs (5–12
in Fig. 1C) from the (1,3,4,6)IP4 backbone by modification of
its free hydroxyls and dimerization of the modified structures.
Diesteric or dietheric linkages of various sizes (n = 1–3) were
chosen for these 5-O-homodimers, which were synthesized by
means of a diverse and versatile approach. The most useful of
these ligands (8, 10 and 12) bind to IP3R1 with an aﬃnity com-
parable to that of the best available competitive antagonist of
IP3R, heparin, the utility of which is limited by its oﬀ-target
eﬀects.
Results and discussion
Chemistry
Synthesis of IP4s and IP5. Phosphates 2–4 were all prepared
from myo-inositol (13) (Scheme 1). Thus, tetrasodium (1,3,4,6)IP4
(2) was synthesized from butanedione-derived acetal 1425 follow-
ing a previously published route.26 Pentasodium (1,2,3,4,6)IP5 (4)
was reached via pentol 15a and pentakis phosphate 15b. Modifi-
cations on the perphosphorylation and hydrogenolysis proto-
cols,26 of an inositol biscyclohexylidene acetal originated
synthetic scheme,27 were applied in order to solely obtain the
pentasodium salt. The preparation of butanoate 3 involved a
novel approach. Thus, acetal 14 was initially selectively pro-
tected at the C-2 position as the PMB ether to yield 16a.
Masking of the remaining C-5 hydroxyl as the benzyl ether
gave the fully protected derivative 16b, which was very carefully
deprotected28 upon treatment with aqueous DDQ to reach free
alcohol 16c. Introduction of the required butyryl group was
performed by esterification with butyric anhydride. The result-
ing ester (16d) was then exposed to aqueous TFA to cleave both
acetals, and the corresponding tetraol (17a) was formed quan-
titatively. Perphosphorylation of crude 17a was accomplished
using a 1H-tetrazole solution in acetonitrile and dibenzyl N,N-
diisopropylphosphoramidate at ambient temperature, followed
by direct oxidation of the intermediate phosphite with m-chlor-
operbenzoic acid at low temperature. Finally, the obtained
benzyl tetrakisphosphate 17b was subjected to hydrogenolysis
Fig. 1 Structures of the ligands used. (A) Key contacts between (1,4,5)
IP3 and residues within the IP3-binding core (IBC) of IP3R1 (Protein Data
Bank 1N4K).9 P4 and P5 form the most extensive interactions (not all are
shown) with residues in the β- (in green) and α-domains (in blue) of
the IBC, respectively, pulling the two domains towards each other.23 P1
and the 6-hydroxyl enhance aﬃnity through hydrogen bonding with
one residue each within the α-domain. (B) (1,4,5)IP3 (1) showing the
essential vicinal (4,5)-bisphosphate (blue) and 6-hydroxyl and 1-phos-
phate required for high-aﬃnity binding (green). Analogs (2–4) are
shown in conﬁgurations most likely to reﬂect their interaction with IP3R
to allow comparison with (1,4,5)IP3. Numbers in brackets refer to equi-
valent groups of (1,4,5)IP3. Diﬀerences from (1,4,5)IP3 are highlighted in
red. (C) Structures of the dimeric analogs and the acyl or alkyl linkers
used.
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in ethanol/water in the presence of Pd/C and sodium bicarbon-
ate (exactly one equivalent per phosphate group) to yield quan-
titatively the desired tetrasodium salt 3.
Synthesis of dimeric analogs of IP4 and IP5. For the syn-
thesis of dimers 5–12, we envisioned the retrosynthetic analy-
sis depicted in Scheme 2. Dimers 5–12 could be reached from
the corresponding polyols 18 applying sequentially perpho-
sphorylation and global deprotection protocols. The key to
obtain all these compounds, diﬀerentially substituted on C-2,
from a common intermediate (19) was to introduce orthogonal
protective groups (PG and PG′) at an early stage of the syn-
thesis. In this way, 19 could serve as the sole precursor for
both series (2-O-butyrylated and 2-O-phosphorylated deriva-
tives) by selective removal of PG′. Esters and ethers 19 could,
in turn, be prepared by dimerization of the corresponding
monomers 20 using the appropriate linkers. Since this process
involved the relatively hindered secondary alcohols 20, we were
keen to explore the feasibility of this approach. Finally, starting
from myo-inositol (13) selective introduction of the required
protective groups was expected to lead to monomers 20.
Monobenzyl ether 21 (Scheme 3) was recognized as a suit-
able derivative, appropriately functionalized to play the role of
20. Moreover 21 is easily accessible25,29,30 from myo-inositol
through butanedione bisacetal 14. Direct dimerization of this
compound was initially investigated using the Steglich esterifi-
cation approach31 and employing malonic (n = 1) and succinic
acid (n = 2) as linkers (Scheme 3 and Table S1 in ESI†).
However, these apparently simple couplings were found to be
complicated, under various reaction conditions tested, by the
formation of acetate 22 (in the first case) and N-acylureas 24a–c
(in both cases). Thus, for malonic acid reactions, the presence
Scheme 1 Synthesis of phosphates 2–4. Reagents and conditions: (a) ref. 25; (b) ref. 26; (c) ref. 27; (d) i. (BnO)2PN(iPr)2, 1H-tetrazole, CH3CN, 25 °C,
48 h; ii. m-CPBA, CH2Cl2, −50 to 0 °C, 5 h, for 15b 73%, for 17b 63%; (e) Pd/C, H2 (1 atm), NaHCO3, EtOH/H2O (1 : 1), 25 °C, 48–96 h, for 3 and 4
100%; (f ) i. NaH, DMF, 0 °C, 1 h; ii. PMBCl, 0 to 25 °C, 12 h, 67%; (g) i. NaH, DMF, 0 °C, 1 h; ii. BnBr, 0 to 25 °C, 12 h, 90%; (h) DDQ, CH2Cl2/H2O
(10 : 1), 25 °C, 24 h, 71%; (i) Bt2O, Et3N, DMAP, CH2Cl2, 25 °C, 12 h, 91%; ( j) 90% aq. TFA, CH2Cl2, 25 °C, 2 h, 100%.
Scheme 2 Retrosynthetic analysis for target dimers 5–12.
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of DMAP seemed to solely favor the decarboxylation
process, regardless of the carbodiimide (DCC or DIC) and the
solvent used.32 We could not securely determine whether this
decarboxylation occurred prior to or after the first esterification.
However, in other runs we isolated the N-acylureas 24a
and 24b, suggesting that acetate 22 is formed from malonic
monoester. Although replacing DMAP with DIPEA eliminated
this problem, the only product isolated was N-acylurea 24b, in
very low yield, whereas starting material was quantitatively
recovered when EDC was used. On the other hand, the reactions
performed in the absence of base33 were productive, yielding
the desired dimer (23a) along with the corresponding N-acylurea
(24a or 24b). The best results were obtained in the case of the
DCC-promoted coupling.34 Surprisingly, applying the same
conditions (DCC in Et2O) for the coupling of 21 with succinic
acid was unsuccessful. In order to reach dimer 23b the presence
of DMAP was a crucial factor using either DCC or EDC in
CH2Cl2.
34 Again, the reaction with DCC furnished an insepar-
able mixture of dimer 23b and N-acylurea 24c, which was
subsequently resolved upon hydrogenolysis. In contrast to
Scheme 3 Synthesis of dimers 23 and 25. Reagents and conditions: (a) ref. 29, 30; (b) CH2(COOH)2, DCC or DIC, DMAP, CH2Cl2, 25 °C, 24 h,
37–41%; (c) CH2(COOH)2, DCC, Et2O, 25 °C, 24 h, 62% of 23a and 12% of 24b; (d) HOCO(CH2)2COOH, DCC, DMAP, CH2Cl2, 25 °C, 96 h, 56% of 23b
and 12% of 24c; (e) TsOCH2(CH2)nCH2OTs (26 or 27), KOH, BnH/DMSO (4 : 1), 55 °C, 120 h, for 25a 45%, for 25b 62%.
Scheme 4 Synthesis of dimeric phosphates 5–12. Reagents and conditions: (a) Pd/C, H2 (1 atm), MeOH, 25 °C, 24 h, 93–100%; (b) Bt2O, Et3N,
DMAP, CH2Cl2, 25 °C, 24 h, 79–97%; (c) 90% aq. TFA, CH2Cl2, 25 °C, 2 h, 98–100%; (d) i. (BnO)2PN(iPr)2, 1H-tetrazole, CH3CN, 25 °C, 48 h;
ii.m-CPBA, CH2Cl2, −50 to 0 °C, 5 h, 60–78%; (e) Pd/C, H2 (1 atm), NaHCO3, EtOH/H2O (1 : 1), 25 °C, 48–72 h, 95–100%.
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esters 23a,b, the synthesis of dimeric ethers 25a,b was accom-
plished in a more facile way. Williamson etherifications,
through the in situ formed (NaH) sodium alkoxide of 21, were
initially attempted in DMF using the required diiodo- or
dibromo-alkanes, but with poor results. Replacing halo-electro-
philes with the more reactive ditosylates 2635 and 2736 and
applying a protocol37 which involved KOH as base and a more
polar solvent (DMSO) furnished the desired dimers (25a,b) in a
clean way and in good yields.38
With the key intermediate dimers in our hands, we pro-
ceeded to the next steps, which involved installation of the
butyryl and phosphate groups. Pd-catalyzed hydrogenolysis of
23a,b and 25a,b led to the corresponding diols 28, which were
esterified upon exposure to butyric anhydride to give 29 in very
good yields (Scheme 4).
Both 28 and 29 were then used to reach the final targets.
Thus, careful treatment of these dimers (especially in the case
of 29) with aqueous TFA furnished octaols and decaols 30, in
nearly quantitative yields (Scheme 4). Perphosphorylation of
these crude polyols was accomplished as described for 17b
(Scheme 1) to obtain the protected polyphosphates 31. The
latter were debenzylated upon hydrogenolysis in the presence
of sodium bicarbonate to yield the octakis and decakis phos-
phate salts 5–12.39
Biology
(1,3,4,6)IP4 is a full agonist of IP3R. Both (1,4,5)IP3 (1) and
(1,3,4,6)IP4 (2) stimulated a concentration-dependent release
of Ca2+ from the intracellular stores of permeabilized DT40-
IP3R1 cells (Fig. 2A and B). The maximal Ca
2+ release evoked
by each ligand was similar, but (1,3,4,6)IP4 was 21 ± 3-fold less
potent that (1,4,5)IP3 (Table S2 in ESI†). Membranes from Sf9
cells expressing rat IP3R1 (Sf9-IP3R1 cells) were used for equili-
brium competition binding studies with 3H-(1,4,5)IP3 because
these membranes express full-length IP3R1 at ∼20-fold higher
levels than cerebellar membranes, the richest source of endo-
genous IP3R1 (Fig. 2C, inset). In these binding analyses, the equi-
librium dissociation constants (Kd) for (1,4,5)IP3 and (1,3,4,6)IP4
diﬀered by 46 ± 19-fold (Fig. 2C and Table S2 in ESI†).
Because both agonists (1 and 2) released the same amount
of Ca2+ at maximally eﬀective concentrations, a comparison of
EC50 and Kd values allows the eﬀectiveness with which each
promotes opening of the IP3R Ca
2+ channel to be determined.
A partial agonist needs to occupy more receptors to elicit the
same response, which is then reflected in a higher EC50/Kd
ratio (and a lower value for pEC50–pKd, where p denotes the
negative log).6 (1,3,4,6)IP4 and (1,4,5)IP3 did not diﬀer signifi-
cantly in their pEC50–pKd values (Table S2 in ESI†) suggesting
that (1,4,5)IP3 and (1,3,4,6)IP4 have similar eﬃcacies. We con-
clude that (1,3,4,6)IP4 is a full agonist with lower aﬃnity than
(1,4,5)IP3, in agreement with a previous report,
21 but inconsist-
ent with suggestions that it is a partial agonist.19,22
2-O-Butyryl-(1,3,4,6)IP4 is a partial agonist and (1,2,3,4,6)IP5
is an antagonist of IP3R. We synthesized and assessed the bio-
logical activity of two analogs with modifications at the 2-posi-
tion of (1,3,4,6)IP4, 2-O-butyryl-(1,3,4,6)IP4 (3) and (1,2,3,4,6)IP5
Fig. 2 2-O-Butyryl-(1,3,4,6)IP4 (3) is a partial agonist and (1,2,3,4,6)IP5
(4) is an antagonist of IP3R1. (A) Typical experiment showing Ca
2+ uptake
into the ER of permeabilized DT40-IP3R1 cells after addition of MgATP
(1.5 mM), recorded with a luminal Ca2+ indicator (mag-ﬂuo4). Addition
of (1,4,5)IP3 (concentrations in nM), with cyclopiazonic acid (CPA,
10 µM) to inhibit the Ca2+ pump, reveals the concentration-dependent
eﬀect of (1,4,5)IP3 on Ca
2+ release. Results show ﬂuorescence (relative
ﬂuorescence units, RFU) as means from triplicate determinations in a
single experiment. (B) Summary results show eﬀects of the indicated
analogs on Ca2+ release (% of Ca2+ content of intracellular stores). (C)
Equilibrium competition binding with 3H-(1,4,5)IP3 and the indicated
analogs using membranes from Sf9-IP3R1 cells in CLM containing
1.5 mM MgATP. Results in B and C are means ± s.e.m., n = 3. The inset
shows a representative Western blot (n = 2) demonstrating expression of
IP3R1 in membranes from rat cerebellum (5 µg protein) and Sf9-IP3R1
cells (0.3 µg). Data summarized in ESI in Table S2.†
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(4) (Fig. 1B). The analogs retained both the essential pharmaco-
phore (Fig. 1B, blue), and the 5-hydroxyl and 6-phosphate
groups [equivalent to the 6-hydroxyl and 1-phosphate of
(1,4,5)IP3] that increase binding aﬃnity (Fig. 1B, green).
A maximally eﬀective concentration of 2-O-butyryl-(1,3,4,6)IP4
released a smaller fraction of the intracellular Ca2+ stores
than did (1,4,5)IP3 (Fig. 2B) and it bound to the IP3R1 with
50 ± 22-fold lower aﬃnity than (1,4,5)IP3 (Fig. 2C). The lesser
maximal Ca2+ release evoked by 2-O-butyryl-(1,3,4,6)IP4,
suggests that it is less eﬃcacious than (1,4,5)IP3. Although 2-O-
butyryl-(1,3,4,6)IP4 and (1,3,4,6)IP4 diﬀered in their ability to
evoke Ca2+ release, they bound to IP3R with similar aﬃnities
(Fig. 2C and Table S2 in ESI†). Hence, addition of a butyryl
moiety to the 2-position of (1,3,4,6)IP4 decreased eﬃcacy
without aﬀecting aﬃnity. 2-O-Butyryl-(1,3,4,6)IP4 (3) thus
replaced (1,3,4,6)IP4 as a lead compound from which we
attempted to develop ligands that bind to IP3R without activat-
ing it (i.e. competitive antagonists).
Even a very high concentration (100 µM) of (1,2,3,4,6)IP5 (4)
failed to release Ca2+ (Fig. 2B), but it bound to IP3R1 with a Kd
of 22.9 µM (Fig. 2C and Table S2 in ESI†). Hence, (1,2,3,4,6)IP5
has 230 ± 100-fold lower aﬃnity than (1,4,5)IP3 for IP3R1 and
significantly lower aﬃnity than (1,3,4,6)IP4 or 2-O-butyryl-
(1,3,4,6)IP4 (5.2 ± 0.5 and 4.8 ± 0.3-fold lower, respectively)
(Fig. 2C, and Table S2, ESI†). (1,2,3,4,6)IP5 retains the essential
pharmacophore and moieties known to be crucial for high-
aﬃnity binding (Fig. 1B), but it has an axial phosphate at the
2-position [equivalent to the 3-position of (1,4,5)IP3]. Others
have reported that an axial phosphate at the 3-position of
(1,4,5)IP3 reduced aﬃnity.
40 The important observation is that
addition of an axial 2-phosphate to (1,3,4,6)IP4, to give
(1,2,3,4,6)IP5, abolishes residual eﬃcacy, albeit with some
(5.2 ± 0.5-fold) loss of aﬃnity.
Pre-equilibration of permeabilized DT40-IP3R1 cells with
(1,2,3,4,6)IP5 (100 µM, 2 min), shifted the sensitivity of the
Ca2+ release evoked by (1,4,5)IP3 by 2.4 ± 0.2-fold, without
aﬀecting either the maximal Ca2+ release or Hill coeﬃcient
(Fig. 3 and Table S3, ESI†). From the dose ratios (see Experi-
mental section), this functional analysis suggests that
(1,2,3,4,6)IP5 binds to the (1,4,5)IP3-binding site of IP3R1 with
a Kd of ∼70 µM. Given the non-equilibrium conditions and the
diﬀerent temperatures used for functional (20 °C) and radioli-
gand binding (4 °C) experiments, this measurement is in
reasonable agreement with the aﬃnity determined from equili-
Fig. 3 (1,2,3,4,6)IP5 (4) and a dimeric analog (6) are competitive anta-
gonists of IP3R1. (A) Typical experiment showing the Ca
2+ content of the
ER after addition of Mg-ATP to permeabilized DT40-IP3R1 cells, followed
by addition of 4 or 6 (100 µM, antagonist) and then cyclopiazonic acid
with (1,4,5)IP3 (100 nM the three upper lighter lines, or 100 µM darker
lines). Results show ﬂuorescence as means from 4 repeats within one
experiment. (B) Summary shows the concentration-dependent eﬀects of
(1,4,5)IP3 on Ca
2+ release alone or after preincubation with 4 or 6
(100 µM). Results are means ± s.e.m., n = 3. Summary results in ESI in
Table S3.†
Fig. 4 Dimers of 2-O-butyryl-(1,3,4,6)IP4 (5, 7, 9, 11) or (1,2,3,4,6)IP5 (6,
8, 10, 12) are competitive antagonists of IP3R1. (A, B) Experiments similar
to those shown in Fig. 3 were used to assess the eﬀects of the indicated
concentrations of (1,4,5)IP3 on Ca
2+ release from permeabilized DT40-
IP3R1 cells after preincubation (2 min) with the indicated dimers (5–12,
100 µM). Results are means ± s.e.m., n = 3. Summary results in Table 1.
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brium binding to IP3R1 (Kd ∼ 23 µM) (Fig. 2C, 3B and Tables
S2, S3 in ESI†). These results demonstrate that (1,2,3,4,6)IP5 is
a competitive antagonist of IP3R with an aﬃnity of ∼20–70 µM.
Dimeric analogs of 2-O-butyryl-(1,3,4,6)IP4 or (1,2,3,4,6)IP5
are antagonists of IP3R1 with reasonable aﬃnity. We reasoned
from past precedent6 that dimeric versions of 2-O-butyryl-
(1,3,4,6)IP4 or (1,2,3,4,6)IP5 might improve aﬃnity or [for 2-O-
butyryl-(1,3,4,6)IP4] the loss of eﬃcacy. We linked 2-O-butyryl-
(1,3,4,6)IP4 and (1,2,3,4,6)IP5 through the 5-O-position [analo-
gous to the 6-hydroxyl of (1,4,5)IP3] to provide homo-dimeric
ligands (5–12, Fig. 1C).
The activities of (1,2,3,4,6)IP5 (4) and the dimer 6 are
directly compared in Fig. 3. Neither 4 nor 6 (100 µM) evoked
Ca2+ release, but they reduced the sensitivity of the Ca2+
release evoked by (1,4,5)IP3 by 2.4 ± 0.2 and 20.9 ± 0.7-fold,
respectively, without aﬀecting the maximal response or Hill
coeﬃcient. Hence the dimer 6, like the monomer 4, is a com-
petitive antagonist, but 6 has an apparent aﬃnity that is 8.8 ±
1.0-fold greater than 4 (Table S3 in ESI†).
The results with 6, suggesting that a dimer of (1,3,4,5,6)IP5
retained the lack of eﬃcacy of (1,3,4,5,6)IP5 while displaying
improved aﬃnity, prompted analysis of seven additional
dimeric analogs of 2-O-butyryl-(1,3,4,6)IP4 and (1,2,3,4,6)IP5
(Fig. 1C). None of the dimers (5–12, 100 µM) evoked Ca2+
release, and they all significantly decreased the sensitivity to
(1,4,5)IP3 without aﬀecting the maximal Ca
2+ release or Hill
coeﬃcient (Fig. 4 and Table 1). All of the dimers (5–12) are
therefore competitive antagonists.
Although 2-O-butyryl-(1,3,4,6)IP4 is a partial agonist with a
Kd of 4.8 µM (Fig. 2B and Table S2 in ESI†), its dimeric analogs
are competitive antagonists with slightly reduced apparent
aﬃnities (Kd = 15–44 µM) (Table 1). The decreased aﬃnity is
consistent with evidence from analogs of (1,4,5)IP3, where sub-
stitution of the 6-hydroxyl (equivalent to the 5-hydroxyl of 3,
through which the dimers are linked) reduced aﬃnity.41,42 The
6-hydroxyl of (1,4,5)IP3 is thought to stabilize interactions of
the IP3-binding core.
7 However, the reduction in aﬃnity
between 3 and its dimers is modest by comparison with the 70
to 100-fold decrease for 6-deoxy-(1,4,5)IP3 and 6-methoxy-
(1,4,5)IP3 relative to (1,4,5)IP3.
41,42 Hence, dimerization of 2-O-
butyryl-(1,3,4,6)IP4, to give 5, 7, 9 and 11, successfully reduced
eﬃcacy, but without improving aﬃnity (Table 1).
The antagonist 12 is one of three dimers of (1,2,3,4,6)IP5 (4)
with equally high aﬃnity, and it shifted the EC50 for (1,4,5)IP3
by 19.4 ± 6.5-fold, suggesting an apparent Kd of ∼7 µM
(Fig. 4B). Given the similar aﬃnities of the dimers 8, 10 and 12
(Kd 7–8 µM) in functional assays (Table 1), we examined only
12 in equilibrium competition binding experiments. The Kd
value for 12 determined in these experiments (7.7 µM) concurs
with the results from functional analyses (Table 1).
These results establish that 8, 10 and 12 are competitive
antagonists of IP3R with low-micromolar aﬃnity. Although
modifications of the 6-hydroxyl of (1,4,5)IP3 reduced
aﬃnity,41,42 dimerization through the analogous 5-hydroxyls of
3 and 4 caused more modest decreases or increases in aﬃnity,
respectively (Table 1). That pattern is similar across the four
diﬀerent linkers used (Fig. 1C). For each linker, dimers of 4
had 2 to 3-fold greater aﬃnity than dimers of 3, even though
monomeric 4 has significantly lower aﬃnity than monomeric
3 (Fig. 4, Tables 1 and S2 in ESI†). For dimers of both 3 and 4,
the shortest linker (n = 1, Fig. 1C) less eﬀectively increased
aﬃnity than did the longer linkers (n = 2–3) (Table 1).
Conclusions
There is a need for selective antagonists of IP3Rs.
17 Aiming to
discover new lead-compounds of this type, a series of novel
(1,3,4,6)IP4 and (1,2,3,4,6)IP5 homodimers were synthesized
following a practical synthetic strategy. Among these homodi-
mers, ligands 8, 10 and 12 were the antagonists with greatest
aﬃnity for IP3R (Kd 7–8 µM). 5-Carboxymethyl-(1,4)IP2 was
reported to partially inhibit IP3-evoked Ca
2+ release, but only at
an extremely high concentration (5 mM).43 (1,3,4,5,6)IP5 is the
only other inositol phosphate previously shown to be a com-
petitive antagonist, but it bound to IP3R1 with lower aﬃnity
Table 1 Dimers of 2-O-butyryl-(1,3,4,6)IP4 and (1,2,3,4,6)IP5 are competitive antagonists of IP3R
a
Ca2+ release Binding
pEC50 (/M) ΔpEC50 (/M) EC50 (nM) Maximal release (%) nH Kd (µM) pKd (/M) Kd (µM)
(1,4,5)IP3 7.03 ± 0.02 — 94 70 ± 1 1.31 ± 0.18 — 6.90 ± 0.19 0.13
+5 6.51 ± 0.06* 0.51 ± 0.03 306 65 ± 6 0.86 ± 0.17 44
+6 6.03 ± 0.06* 1.00 ± 0.07 931 58 ± 4 1.28 ± 0.08 11 4.79 ± 0.05 16.4
+7 6.14 ± 0.08* 0.89 ± 0.08 719 59 ± 4 1.67 ± 0.57 15
+8 5.89 ± 0.11* 1.14 ± 0.09 1300 60 ± 5 1.49 ± 0.39 8
+9 6.24 ± 0.07* 0.79 ± 0.09 571 64 ± 4 1.63 ± 0.42 20
+10 5.86 ± 0.06* 1.17 ± 0.05 1393 64 ± 3 1.58 ± 0.17 7
+11 6.27 ± 0.13* 0.76 ± 0.15 537 59 ± 4 1.08 ± 0.17 21
+12 5.84 ± 0.16* 1.19 ± 0.18 1449 60 ± 5 2.13 ± 0.55 7 5.11 ± 0.08 7.7
a Summary results from Fig. 4 show the eﬀects of (1,4,5)IP3 alone or in the presence of 100 µM of each analog. Results show pEC50, ΔpEC50
(pECcontrol50 –pEC
antagonist
50 ) and Hill coeﬃcients (nH) (means ± s.e.m.) and EC50 for (1,4,5)IP3-evoked Ca
2+ release (n = 3). Kd is shown calculated
from functional assays and from equilibrium competition binding experiments (n = 3). Statistical diﬀerences were determined by one-way ANOVA
and Tukey’s post hoc test, and refer to the results with (1,4,5)IP3 alone, *P < 0.05.
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(Kd ∼40 µM)44 than (1,2,3,4,6)IP5 (4, Kd ∼ 23 µM) and with
substantially lower aﬃnity than the dimers of 4. These com-
parisons are consistent with our observation that 10 µM
(1,2,4,5,6)IP5 had no detectable eﬀect on (1,4,5)IP3-evoked Ca
2+
release,6 whereas the same concentration of 12 caused a
2.8-fold decrease in (1,4,5)IP3-sensitivity (not shown). A
dimeric benzene with six attached phosphate groups (biphenyl
2,2′,4,4′,5,5′-hexakisphosphate) was recently reported to be a
rather high-aﬃnity (Kd ∼ 200 nM) antagonist of IP3R, but it
inhibited IP3 5-phosphatase with very similar potency.
45 Com-
pounds 8, 10 and 12 are the most potent inositol phosphate-
based antagonists of IP3R so far reported. The aﬃnity of these
antagonists for IP3R1 (Kd 7–8 µM) is comparable to that of
heparin (Kd ∼ 4 µM),17 but the new dimeric antagonists are
smaller than heparin (Mr ∼1200 and ∼5000, respectively), and
less likely to interact with as many additional intracellular
targets. None of these antagonists is membrane-permeant, but
based on the versatility of our synthetic approach, it may be
feasible to esterify the phosphate groups of the dimeric antag-
onists to allow them to cross the plasma membrane and then
be de-esterified by endogenous intracellular esterases.46
Experimental
Chemistry
Materials and methods. All commercially available reagent-
grade chemicals and solvents were used without further purifi-
cation. Dry solvents were prepared by literature methods and
stored over molecular sieves. Whenever possible, reactions
were monitored using commercially available precoated TLC
plates (layer thickness 0.25 mm) of Kieselgel 60F254. Com-
pounds were visualized by use of a UV lamp and/or phospho-
molybdic acid (PMA) or Seebach’s stains upon warming.
Column chromatography was performed in the usual way
using Merck 60 (40–60 mm) silica gel using as eluents the sol-
vents indicated in each case. Yields are reported for isolated
compounds with >96% purity, as established by NMR spec-
troscopy. FTIR spectra were obtained in a Nicolet 6700 spectro-
meter. NMR spectra were recorded with a 300 MHz Bruker
Avancelli spectrometer (1H: 300 MHz, 13C: 75 MHz, 31P:
121 MHz) or an Agilent 500/54 spectrometer (1H: 500 MHz,
13C: 126 MHz, 31P: 202 MHz) using the deuterated solvent indi-
cated. Chemical shifts are given in parts per million and
J values in Hertz using solvent or TMS as an internal reference.
Assignments of protons were confirmed based on 2D NMR
experiments (1H, 1H COSY, HSQC, and HMBC, recorded using
a standard pulse-program library). High resolution mass
spectra (HRMS) were recorded on micrOTOF GC-MS QP 5050
Shimadzu single-quadrupole mass spectrometer. For each
known compound 1H and/or 13C NMR spectra along with
HRMS spectra were used to establish identity.
Esterification of malonic acid with 21. Malonic acid
(280 mg, 2.69 mmol), and DCC (4.43 g, 21.5 mmol) were suc-
cessively added to a solution of alcohol 21 (2.69 g, 5.39 mmol)
in dry Et2O (50 mL). The resulting slurry was vigorously stirred
under an Ar atmosphere at room temperature for 24 h, while
the reaction progress was monitored by TLC. Upon com-
pletion, the solvent was removed in vacuo. The residue was tri-
turated with Et2O and filtered. The solid was further washed
with Et2O (25 mL) and the filtrates were concentrated in vacuo
and the residue was purified with flash column chromato-
graphy (hexanes/EtOAc 5 : 1 to 2 : 1) to give 1.78 g (62%) of
diester 23a and 510 mg (12%) of ureido derivative 24b.
Esterification of succinic acid with 21. Succinic acid
(160 mg, 1.36 mmol), DMAP (133 mg, 1.1 mmol), and DCC
(1.69 g, 8.2 mmol) were successively added to a solution of
alcohol 21 (1.36 g, 2.72 mmol) in dry CH2Cl2 (25 mL). The
resulting slurry was vigorously stirred under an Ar atmosphere
at room temperature for 96 h, while the reaction progress was
monitored by TLC. Upon completion, the reaction mixture was
washed with H2O (25 mL) and saturated brine (25 mL). The
combined aqueous phases were back-extracted with CH2Cl2
(4 × 50 mL), the combined organic phases were dried over
Na2SO4, and the solvents were removed in vacuo. The residue
was purified with flash column chromatography (hexanes/
EtOAc 3 : 1 to 1 : 1) to give 820 mg (56%) of diester 23b and
260 mg (12%) of ureido derivative 24c.
General procedure A: preparation of 5,5′-ethers 25a,b. Alco-
hol 21 (1 mmol) was dissolved in a 4 : 1 mixture of toluene and
DMSO (2.5 mL), powdered KOH (140 mg, 2.5 mmol) was
added and the mixture was warmed up to 55 °C. Then, 2635 or
2736 (0.5 mmol) was added in one portion and the resulting
slurry was heated at the same temperature for 120 h, while the
progress of the reaction was monitored by TLC. Upon com-
pletion, the mixture was neutralized with the addition of a
saturated aqueous NH4Cl solution. Then, water was added to
dissolve all solids and the clear solution was extracted with
toluene (50 mL) and CH2Cl2 (2 × 50 mL). The combined
organic phases were dried over Na2SO4, and concentrated in
vacuo. The residue was purified with flash column chromato-
graphy (hexanes/EtOAc 5 : 1 to 1 : 1) to give ethers 25a,b.
General procedure B: preparation of diols 28. 10% Pd/C
(200 mg) was added to a solution of dibenzyl ether 23 or 25
(1 mmol) in MeOH (60 mL). This mixture was vigorously
stirred under H2 (1 atm) at room temperature for 24 h. Then, it
was filtered through a pad of Celite®, which was further
washed with MeOH (20 mL), CH2Cl2 (20 mL), and MeOH
(20 mL). Diols 28 were found to be suﬃciently pure and used
in the next steps without any further purification.
General procedure C: preparation of butyrates 29. Dry Et3N
(0.56 mL, 4 mmol) and DMAP (50 mg, 0.4 mmol) were added
to a solution of diol 28 (1 mmol) in dry CH2Cl2 (10 mL) under
an Ar atmosphere at room temperature. Butyric anhydride
(0.50 mL, 3 mmol) was added and the mixture was stirred at
room temperature until the full consumption of starting
material (TLC monitoring, about 24 h). The reaction mixture
was diluted with CH2Cl2 (20 mL) and successively washed with
saturated aqueous sodium bicarbonate solution (3 × 10 mL)
and saturated brine (10 mL). The aqueous phase was back-
extracted with CH2Cl2 (10 mL) and the combined organic
phases were dried over Na2SO4 and concentrated in vacuo. The
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residue was purified with flash column chromatography
(hexanes/EtOAc 7 : 1 to 1 : 1) to give butyrates 29.
General procedure D: removal of acetal protecting groups. A
90% aqueous solution of TFA (10 mL) was added dropwsise to
a solution of starting acetal (16d or 28 or 29, 1 mmol) in
CH2Cl2 (10 mL) at room temperature. The resulting mixture
was stirred at the same temperature for 2 h. Then, the volatiles
were removed under reduced pressure (40 °C). The residue was
successively treated with toluene (10 mL) and absolute EtOH
(3 × 10 mL) and each time the solvent was removed under
reduced pressure. The resulting polyol was found to be
suﬃciently pure by NMR and used in the next step without
any further purification.
General procedure E: phosphorylation of polyols. A 0.45 M
solution of 1H-tetrazole in CH3CN (3 equiv. per OH) was added
to a flask containing neat starting polyol (15a or 17a or 30,
1 mmol) under an Ar atmosphere at room temperature. Then,
dibenzyl N,N-diisopropylphosphoramidite (1.6 equiv. per OH)
was added dropwise over a period of 30 min. The resulting
mixtrure was stirred for 24 h at room temperature, and an
additional amount of the phosphorylating agent was added
(0.3 equiv. per OH). After 24 h the reaction mixture was diluted
with CH2Cl2 (10 mL) and cooled to −50 °C. A solution of 70%
m-CPBA (2.4 equiv. per OH) in CH2Cl2 (1.6 mL per mmol
m-CPBA) was added dropwise and the mixture was left to vigor-
ously stir for 5 h at 0 °C. The reaction mixture was further
diluted with CH2Cl2 (120 mL) and successively washed with a
10% aqueous solution of sodium sulfite (2 × 150 mL), a satu-
rated aqueous solution of NaHCO3 (2 × 120 mL), and H2O
(120 mL). The combined aqueous phases were back-extracted
with CH2Cl2 (100 mL). The combined organic phases were
washed with saturated brine (120 mL), and dried over Na2SO4.
The solvents were removed under reduced pressure and the
residue was purified with flash column chromatography
(initially hexanes/EtOAc 2 : 1 to 1 : 2 and then 2–5% CH3OH in
EtOAc).
General procedure F: final deprotection. The starting benzyl
phosphate (15b or 17b or 31, 1 mmol) was dissolved in EtOH
(50–70 mL). Deionized H2O (50–70 mL) and NaHCO3 (1 equiv.
per phosphate group) were added. Then, 10% Pd/C (1 g) was
added to the resulting emulsion and the mixture was vigor-
ously stirred under H2 (1 atm) at room temperature for the
indicating period of time. The reaction progress was moni-
tored by 1H NMR. Upon completion the catalyst was removed
by filtration through an LCR/PTFE hydrophilic membrane
(0.5 mm); the membrane was washed with a 1 : 1 mixture of
EtOH and deionized H2O (3 × 30 mL). The combined filtrates
were evaporated under reduced pressure (55 °C), and the
resulting residue was dried under high vacuum for 24 h to
yield the desired phosphate salt.
Biology
Ca2+ release from permeabilized DT40-IP3R1 cells. DT40
cells with disrupted endogenous IP3R genes, and stably expres-
sing rat IP3R1 (DT40-IP3R1 cells) were cultured as described.
47
For measurements of free [Ca2+] within the lumen of the ER,
cells were incubated with mag-fluo4/AM (20 µM, Life Techno-
logies, Paisley, UK) under conditions that favor sequestration
of the indicator into the ER lumen.48 Cells were washed, per-
meabilized using saponin, resuspended in cytosol-like
medium (CLM) supplemented with FCCP [10 μM, carbonyl
cyanide 4-(trifluoromethoxy)phenylhydrazone] to inhibit mito-
chondria, and distributed into black half-area 96-well plates
(Greiner Bio-One).48 CLM had the following composition:
2 mM NaCl, 140 mM KCl, 1 mM EGTA, 20 mM PIPES, 375 µM
CaCl2 (free [Ca
2+] ∼230 nM), pH 7.0. Fluorescence (excitation
at 485 nm, emission at 525 nm) was recorded at 1.44 s
intervals at 20 °C using a FlexStation 3 plate-reader (MDS
Analytical Devices, Berkshire, UK).48 Ca2+ uptake into the ER
was initiated by addition of 1.5 mM MgATP, and after 2 min
(1,4,5)IP3 or an analog was added with cyclopiazonic acid
(CPA, 10 µM, R&D Systems Europe, Oxford, UK) to inhibit
further Ca2+ uptake. Ca2+ release was recorded after a further
10–20 s and reported as a fraction of the Ca2+ uptake evoked
by ATP. Antagonists were added 2 min before (1,4,5)IP3.
Equilibrium binding of 3H-(1,4,5)IP3 and competing ligands
to IP3R1. These assays were performed at 4 °C in 500 µL of
CLM containing 1.5 mM MgATP, membranes (∼20 µg protein)
prepared from Sf9 cells expressing rat IP3R1 (Sf9-IP3R1 cells),
3H-(1,4,5)IP3 (1.5 nM, 19.3 Ci per mmol, Perkin Elmer,
Waltham, MA, USA) and appropriate concentrations of com-
peting ligand. Non-specific binding was determined by
addition of 10 µM (1,4,5)IP3 (Enzo Life Sciences, Exeter, UK).
Reactions were terminated after 5 min by centrifugation
(20 000g, 5 min, 4 °C). The pellet was washed with 700 µL of
CLM, resuspended in 200 µL of CLM, and radioactivity was
determined by liquid scintillation counting. Culture of Sf9
cells, infection with baculovirus encoding rat IP3R1, and
preparation of membranes were as described previously.49
Quantification of IP3R1 expression by Western blotting, using
an anti-peptide antiserum to IP3R1
49 was performed as
described.50
Analysis. For each individual experiment, concentration-
eﬀect relationships were fitted to a Hill equation using non-
linear curve-fitting (GraphPad Prism, version 5). From each
experiment, pEC50 or pIC50 [−log of the half-maximally
eﬀective (EC50) or inhibitory (IC50) concentration in M], Hill
coeﬃcient (nH), and the maximal response were obtained and
then used for statistical analyses. All reported comparisons of
ligand potencies rely on comparisons within experiments
because EC50 values for (1,4,5)IP3-evoked Ca
2+ release can vary
between passages of cells. For convenience, figures illustrating
concentration-eﬀect relations show average results from
several experiments, but the values (pEC50, etc.) determined
from fitting curves to individual experiments were used for
statistical analyses. Most statistical comparisons were paired,
and used Student’s t-test or one-way ANOVA with Tukey’s post
hoc test as appropriate. P < 0.05 is considered significant.
The dose ratio (DR = EC′50/EC50, where EC′50 and EC50 are
the EC50 values for (1,4,5)IP3-evoked Ca
2+ release determined
in the presence and absence of antagonist, respectively)
was used to calculate the apparent aﬃnity (Kd) of IP3R1 for
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antagonists from functional assays:
Kd ¼ ½AntagonistðDR 1Þ
From equilibrium competition binding experiments, the Kd
of competing ligands was calculated from the concentration
(IC50) required to cause 50% displacement of the specifically
bound 3H-(1,4,5)IP3:
Kd ¼ IC50
1þ ½
3H‐ð1; 4; 5ÞIP3
K ð1;4;5ÞIP3d
The [3H-(1,4,5)IP3] was 1.5 nM, and Kd
(1,4,5)IP3 (127 nM) (ESI
Table S2†). pKd values were then used for statistical analyses.
51
For comparisons of diﬀerences between pEC50 and pKd
values (pEC50–pKd), the standard deviation of the diﬀerence
(σpEC50–Kd) was calculated from the individual variances (σpEC50
and σpKd):
52
σpEC50Kd ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
σpEC50
2  σpKd 2
q
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Abbreviations
Bt Butyryl
CLM Cytosol-like medium
m-CPBA m-Chloro-perbenzoic acid
DCC N,N′-Dicyclohexylcarbodiimide
DDQ 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone
DIC N,N′-Diisopropylcarbodiimide
DMAP 4-Dimethylaminopyridine
EC50
(IC50)
Half-maximal eﬀective (inhibitory) concentration
EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
ER Endoplasmic reticulum
IP3 Inositol trisphosphate
IP3R IP3 receptor
IP4 Inositol tetrakisphosphate
IP5 Inositol pentakisphosphate (structures of the
analogs and their codes are shown in Fig. 1)
Kd Equilibrium dissociation constant
pEC50
(pKd)
−log EC50 (Kd)
PMB p-Methoxybenzyl
TFA Trifluoroacetic acid
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